Assessment of safety and efficacy of Karallief® Easy ClimbTM, an herbal extract blend for supporting joint health: a double-blind, placebo-controlled, randomized clinical trial
Keywords:Knee osteoarthritis, Herbal supplement, Natural treatment, Randomized clinical trial, Joint health, Joint mobility
Background: Osteoarthritis is common among the aging population worldwide. The current techniques to manage osteoarthritis focus on relieving pain and slowing the progression of the disease. Herbal or natural supplements have shown promise in achieving both these treatment goals. Two new proprietary herbal extract blends, Karallief® Easy ClimbTM (KEC) and herbal extracts with glucosamine (HEG), are combinations of several natural products shown to be effective in the treatment of knee osteoarthritis. The current study tested the efficacy and safety of KEC and HEG versus a placebo control.
Methods: This is a randomized, double-blind and placebo-controlled study. A total of 120 patients were divided into 3 groups and were given KEC, HEG and Placebo in the ratio 1:1:1. Treatment results were assessed using the 30 second chair stand test, WOMAC test, knee flexion test and joint space measurement using X-rays of the knee joint.
Results: The study found that the herbal supplements HEG and KEC significantly reduced osteoarthritis-related knee pain and increased joint mobility and were safe to use during 120 days of treatment. Both supplements resulted in an improvement in the 30 second chair stand test results, WOMAC pain scores, knee flexion, and joint space width as measured by X-ray, as compared to the placebo.
Conclusions: Natural supplements such as HEG and KEC improve knee osteoarthritis symptoms and can be a safe and effective treatment option for patients with osteoarthritis.
Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2163-96.
Pal CP, Singh P, Chaturvedi S, Pruthi KK, Vij A. Epidemiology of knee osteoarthritis in India and related factors. Indian J Orthop. 2016;50(5):518-22.
CDC Arthritis, 2020. Available at https://www. https://www.cdc.gov/arthritis/index.html. Accessed on 11/09/2020.
Doherty M, Dieppe P. The "placebo" response in osteoarthritis and its implications for clinical practice. Osteoarthritis Cartilage. 2009;17(10):1255-62.
Gustavo C de Campose. Placebo effect in osteoarthritis: Why not use it to our advantage? World J Orthop. 2015;6(5):416-20.
Felson DT, Lawrence RC, Dieppe PA, Hirsch R, Helmick CG, Jordan JM et al. Osteoarthritis: new insights. Part 1: the disease and its risk factors. Ann Intern Med. 2000;133(8):635-46.
Bruyere O, Honvo G, Veronese N, Arden NK, Branco J, Curtis EM et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019;49(3):337-50.
Ferreira RM, Duarte JA, Goncalves RS. Non-pharmacological and non- surgical interventions to manage patients with knee osteoarthritis: An umbrella review. Acta Reumatol Port. 2018;43(3):182-200.
Mora JC, Przkora R, Cruz-Almeida Y. Knee osteoarthritis: pathophysiology and current treatment modalities. J Pain Res. 2018;11:2189-96.
Fairweather J, Jawad AS. Cardiovascular risk with nonsteroidal anti- inflammatory drugs (NSAIDs): the urological perspective. BJU Int. 2012;110(11):E437.
Ungprasert P, Cheungpasitporn W, Crowson CS, Matteson EL. Individual non-steroidal anti-inflammatory drugs and risk of acute kidney injury: A systematic review and meta-analysis of observational studies. Eur J Intern Med. 2015;26(4):285-91.
Masso Gonzalez EL, Patrignani P, Tacconelli S, Garcia Rodriguez LA. Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding. Arthritis Rheum. 2010;62(6):1592-1601.
Ravalli S, Szychlinska MA, Leonardi RM, Musumeci G. Recently highlighted nutraceuticals for preventive management of osteoarthritis. World J Orthop. 2018;9(11):255-61.
Vaishya R, Agarwal AK, Shah A, Vijay V, Vaish A. Current status of top 10 nutraceuticals used for Knee Osteoarthritis in India. J Clin Orthop Trauma. 2018;9(4):338-48.
Li H, Zeng C, Wei J, Yang T, Gao SG, Li YS et al. Serum Calcium Concentration Is Inversely Associated with Radiographic Knee Osteoarthritis: A Cross-Sectional Study. Medicine (Baltimore). 2016;95(6):e2838.
Gogebakan B, Izmirli M, Okuyan HM, Atac L. Biomarkers for early diagnosis of osteoarthritis. In: Osteoarthritis. SM d books. 2016.
Zanini A, Crisafulli E, D’Andria M, Gregorini C, Cherubino F, Zampogna E, et al Minimal clinically important difference in 30 second sit-to- stand test after pulmonary rehabilitation in patients with COPD. Eur Respiratory J. 2018;52(62):OA5199
CDC. 30-Second Chair Stand 2017. Available at https://www.cdc.gov/steadi/pdf/STEADI- Assessment-30Sec-508.pdf. Accessed on 11/09/2020.
Beattie KA, Duryea J, Pui M, O'Neill J, Boulos P, Webber CE et al. Minimum joint space width and tibial cartilage morphology in the knees of healthy individuals: a cross-sectional study. BMC Musculoskelet Disord. 2008;9;119.
Moroz A. Physical Therapy (PT). Available at https://www.merckmanuals.com/professional/special-subjects/rehabilitation/physical-therapy-pt#v1128315. 2017. Accessed on 11/09/2020.
Loeser RF, Goldring SR, Scanzello CR, Goldring MB. Osteoarthritis: a disease of the joint as an organ. Arthritis Rheum. 2012;64(6):1697-1707.
Vasiliadis HS, Tsikopoulos K. Glucosamine and chondroitin for the treatment of osteoarthritis. World J Orthop. 2017;8(1):1-11.
Huang Z, Chen J, Hu QS, Huang Q, Ma J, Pei FX et al. Meta-s analysis of pain and function placebo responses in pharmacological osteoarthritis trials. Arthritis Res Ther. 2019;21(1):173.
Abhishek A, Doherty M. Mechanisms of the placebo response in pain in osteoarthritis. Osteoarthritis Cartilage. 2013;21(9):1229-35.